GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » COGS-to-Revenue

Notable Labs (Notable Labs) COGS-to-Revenue : 0.64 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs COGS-to-Revenue?

Notable Labs's Cost of Goods Sold for the six months ended in Dec. 2023 was $0.20 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.31 Mil.

Notable Labs's COGS to Revenue for the six months ended in Dec. 2023 was 0.64.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Notable Labs's Gross Margin % for the six months ended in Dec. 2023 was 36.45%.

Notable Labs COGS-to-Revenue Historical Data

The historical data trend for Notable Labs's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs COGS-to-Revenue Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
COGS-to-Revenue
- - 0.64

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
COGS-to-Revenue - - 0.64

Notable Labs COGS-to-Revenue Calculation

Notable Labs's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.197 / 0.31
=0.64

Notable Labs's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.197 / 0.31
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs  (NAS:NTBL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Notable Labs's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.197 / 0.31
=36.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Notable Labs COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Notable Labs's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs (Notable Labs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » COGS-to-Revenue
Comparable Companies
NLSP ACST AGE CRBP NBIO CLRB AIM PLUR BIXT SNSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Website
https://notablelabs.com
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.